Deals this week: DiCE Molecules, Entrega, Ono Pharmaceutical

22nd December 2017 (Last Updated December 22nd, 2017 00:00)

US-based biotechnology company DiCE Molecules has signed an agreement to discover new small molecules against multiple targets using its technology platform in a partnership with Genentech.

US-based biotechnology company DiCE Molecules has signed an agreement to discover new small molecules against multiple targets using its technology platform in a partnership with Genentech.

DiCE Molecules will be entitled to receive undisclosed upfront payment, as well as research, development, regulatory, and commercial milestone payments, upon meeting certain pre-determined milestones.

Entrega has signed an agreement to investigate the application of its peptide delivery technology to the Eli Lilly and Company’s products and therapeutic candidates.

Entrega will receive $5m in equity and research funding under the agreement.

Entrega is a US-based oral drug delivery technologies developer and a subsidiary of Puretech Health, while Eli Lilly is a pharmaceutical company also based in the US.

The deal will enable the two companies to develop proprietary oral delivery technology for peptides.

Japanese pharmaceutical company Ono Pharmaceutical is to develop novel therapeutics using the Schrodinger’s computational drug discovery platform as part of a research collaboration.

Schrodinger is an advanced molecular simulations and enterprise software solutions provider based in the US. It will receive research funding and milestone payments from Ono Pharma as part of the agreement.

Boehringer Ingelheim and F Hoffmann-La Roche Ltd (Roche) have entered a co-development agreement for the development of orally available novel locked nucleic acid (LNA) and oligonucleotides for the treatment of inflammatory bowel diseases (IBDs).

The two companies will share clinical development costs and be responsible for the commercialisation of products developed.

Boehringer Ingelheim is a pharmaceutical company based in Germany, while F Hoffmann-La Roche is a Switzerland-based pharmaceutical company.

"Entrega will receive $5m in equity and research funding under the agreement."

Array BioPharma has signed a clinical trial agreement to investigate the safety and efficacy of a number of novel anti-cancer combinations with Pfizer’s PARP inhibitor talazoparib, and avelumab.

The two companies will collaborate on a Phase Ib clinical trial, which is expected to start in the third quarter of 2018.

US-based urology company Taris Biomedical is to evaluate the safety and efficacy of its X TAR-200 (GemRIS) as part of a clinical trial collaboration with Bristol-Myers Squibb.

The two companies will initiate Phase 1b trial X TAR-200 (GemRIS) in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of muscle-invasive bladder cancer (MIBC).

Bristol-Myers Squibb has also made an equity investment in Taris Biomedical as part of the agreement.

UK-based exosome therapeutics company Evox Therapeutics has signed an agreement with German pharmaceutical company Boehringer Ingelheim to investigate the exosome-mediated delivery of RNAs.

The two companies will carry out in-vitro and in-vivo research using the Evox's exosome technology.

Boehringer Ingelheim will have an option to sign a licence agreement to further develop the RNA drug candidates following completion of the studies.

ClearPath Vaccines Company (CVC) and Astellas Pharma have entered a research agreement with Boston Children's Hospital (BCH) for the development of vaccines to treat staphylococcus aureus infections.

The collaboration will use the vaccine design platform developed at Boston Children's Hospital to develop a vaccine for the treatment of Staphylococcus aureus infections.

ClearPath Vaccines is a US-based vaccine development company and a subsidiary of ClearPath Development Company, while Astellas Pharma is a Japanese pharmaceutical firm.